Day: March 5, 2024

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million Reaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024 Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024 Provides full year 2024 financial guidance Hosts investment community conference call on March 6, 2024WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a progress update on the key 2024 objectives previously...

DENVER, March 05, 2024 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the “Company”) (NASDAQ: ISPO), the innovative luxury travel club, today announced its 2023 fourth quarter and full-year results and provided 2024 guidance aimed at improving its path to profitability. Except as otherwise stated, all financial results discussed below are presented in accordance with generally accepted accounting principles in the United States of America, or GAAP. As supplemental information, we have provided certain additional non-GAAP financial measures in this press release’s supplemental tables, and such supplemental tables include a reconciliation of these non-GAAP measures to our GAAP results. The sum of individual metrics may not always equal total amounts indicated due to rounding. 2023 Fourth Quarter and Full-Year Highlights:Full-year...

TAREN POINT, Australia, March 05, 2024 (GLOBE NEWSWIRE) — Fitell Corporation (Nasdaq: FTEL) (“Fitell” or the “Company”), an online retailer of gym and fitness equipment in Australia, today announced its half-year financial results for the six months ended December 31, 2023. Six-month Period ended December 31, 2023 Financial HighlightsRevenue was $2.1 million, a decrease of $0.9 million or 30.5% compared to the same period in 2022. Gross profit was $0.85 million, a decrease of $745,555 or 46.8% from the same period in 2022.Revenue by Categories vs. Same Period of Prior Year  Revenue Change from Six-month Period ended December 31, 2022  US$ % US$ %Merchandise revenue 2,007,562 94.6% (144,310 ) -6.7%Sales of consumable products 0 0 (605,415 ) -100.0%Revenue from licensing customers 115,557 5.4% (181,308 ) -61.1%Merchandise...

HOUSTON, March 05, 2024 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today reported operational and financial results for the fourth quarter and full year 2023, including the Company’s year-end 2023 reserve report. Detailed guidance for the first quarter of 2024 and full year 2024 was also provided, and W&T announced its dividend for the first quarter of 2024. This press release includes non-GAAP financial measures, including Adjusted Net (Loss) Income, Adjusted EBITDA, Free Cash Flow, Net Debt and PV-10 which are described and reconciled to the most comparable GAAP measures below in the accompanying tables under “Non-GAAP Information.” Key highlights for the fourth quarter and full year 2023 and since year-end 2023 included:Completed two accretive acquisitions of producing properties...

MISSISSAUGA, Ontario, March 05, 2024 (GLOBE NEWSWIRE) — “The robust growth and profitability of Bird’s fourth quarter and full year reflect the power of executing our strategy, the trust and level of collaboration we have achieved with our clients, and the quality of delivery from our dedicated ‘One Bird’ team. Our capabilities to deliver sophisticated work and our position as a leading collaborative construction and maintenance company remain competitive advantages, which we intend to leverage in 2024 and beyond as we continue to focus on growth and margin expansion,” stated Teri McKibbon, President and CEO of Bird Construction. “Supported by a strong balance sheet and ability to generate positive cash flow that allows the Company to invest in profitable organic growth and pursue accretive acquisitions, the Company...

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...